PCNA inhibitors

1. A compound having the formula:

wherein

Ring A is phenyl or 5 to 6 membered heteroaryl;

Ring B is quinolinyl;

R 1 is independently halogen, —CX 1 3 , —CHX 1 2 , —CH 2 X 1 , —CN, —SO n1 R 10 , —SO v1 NR 7 R 8 , —NHNH 2 , —ONR 7 R 8 , —NHC═(O)NHNH 2 , —NHC═(O)NR 7 R 8 , —N(O) m1 , —NR 7 R 8 , —C(O)R 9 , —C(O)—OR 9 , —C(O)NR 7 R 8 , —OR 10 , —NR 7 SO 2 R 10 , —NR 7 C═(O)R 9 , —NR 7 C(O)—OR 9 , —NR 7 OR 9 , —OCX 1 3 , —OCHX 1 2 , —OCH 2 X 1 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two adjacent R 1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is hydrogen, halogen, —CX 2 3 , —CHX 2 2 , —CH 2 X 2 , —CN, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 3 is hydrogen, halogen, —CX 3 3 , —CHX 3 2 , —CH 2 X 3 , —CN, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is independently halogen, —CX 4 3 , —CHX 4 2 , —CH 2 X 4 , —CN, —SO n4 R 14 , —SO v4 NR 11 R 12 , —NHNR 11 R 12 , —ONR 11 R 12 , —NHC═(O)NHNR 11 R 12 , —NHC═(O)NR 11 R 12 , —N(O) m4 , —NR 11 R 12 , —C(O)R 13 , —C(O)—OR 13 , —C(O)NR 11 R 12 , —OR 14 , —NR 11 SO 2 R 14 , —NR 11 C═(O)R 13 , —NR 11 C(O)—OR 13 , —NR 11 OR 13 , —OCX 4 3 , —OCHX 4 2 , —OCH 2 X 4 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two adjacent R 4 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 5 is independently halogen, —CX 5 3 , —CHX 5 2 , —CH 2 X 5 , —CN, —SO n5 R 18 , —SO v5 NR 15 R 16 , —NHNR 15 R 16 , —ONR 15 R 16 , —NHC═(O)NHNR 15 R 16 , —NHC═(O)NR 15 R 16 , —N(O) m5 , —NR 15 R 16 , —C(O)R 17 , —C(O)—OR 17 , —C(O)NR 15 R 16 , —OR 18 , —NR 15 SO 2 R 18 , —NR 15 C═(O)R 17 , —NR 15 C(O)—OR 17 , —NR 15 OR 17 , —OCX 5 3 , —OCHX 5 2 , —OCH 2 X 5 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two adjacent R 5 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 7 , R 8 , R 9 , and R 10 are independently hydrogen, halogen, —CX A 3 , —CHX A 2 , —CH 2 X A , —CN, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or R 7 and R 8 substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

R 11 , R 12 , R 13 , and R 14 and are independently hydrogen, halogen, —CX B 3 , —CHX B 2 , —CH 2 X B , —CN, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or R 11 and R 12 substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

R 15 , R 16 , R 17 , and R 18 are independently hydrogen, halogen, —CX C 3 , —CHX C 2 , —CH 2 X C , —CN, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or R 15 and R 16 substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

z1 is an integer from 0 to 4;

z2 is an integer from 0 to 5;

z3 is an integer from 0 to 6;

m1, m4, m5, v1, v4, and v5 are independently 1 or 2;

n1, n4, and n5 are independently an integer from 0 to 4; and

X 1 , X 2 , X 3 , X 4 , X 5 , X A , X B , and X C are independently —Cl, —Br, —I, or —F.

2. The compound of claim 1 , wherein R 1 is independently halogen, —CF 3 , —OH, —NH 2 , —SH, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.

3. The compound of claim 1 , wherein R 4 is independently halogen, —CF 3 , —OH, —NH 2 , —SH, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.

4. The compound of claim 1 , wherein R 4 is independently —OR 14 , and R 14 is hydrogen or unsubstituted C 1 -C 5 alkyl.

5. The compound of claim 1 , wherein R 5 is independently halogen, —CF 3 , —OH, —NH 2 , —SH, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.

6. The compound of claim 1 , wherein R 2 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

7. The compound of claim 1 , wherein R 3 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

8. The compound of claim 1 , wherein Ring A is phenyl.

9. The compound of claim 1 , wherein Ring A is a 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.

10. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

11. The pharmaceutical composition of claim 10 , further comprising an anti-cancer agent.

12. The pharmaceutical composition of claim 11 , wherein the anti-cancer agent is a platinum-based compound or a topoisomerase inhibitor.

13. The pharmaceutical composition of claim 12 , wherein the anti-cancer agent is etoposide, camptothecin, or gemcitabine.

14. A method of treating a disease associated with PCNA activity in a patient having said disease, said method comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

15. A method of treating cancer in a patient having said cancer, said method comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , further comprising administering radiation.

17. A compound having the formula:

18. A pharmaceutical composition comprising a compound of claim 17 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

19. The pharmaceutical composition of claim 18 , further comprising an anti-cancer agent.

20. The pharmaceutical composition of claim 19 , wherein the anti-cancer agent is a platinum-based compound or a topoisomerase inhibitor.

21. The pharmaceutical composition of claim 20 , wherein the anti-cancer agent is etoposide, camptothecin, or gemcitabine.

22. A method of treating a disease associated with PCNA activity in a patient having said disease, said method comprising administering a therapeutically effective amount of a compound of claim 17 , or a pharmaceutically acceptable salt thereof.

23. A method of treating cancer in a patient having said cancer, said method comprising administering a therapeutically effective amount of a compound of claim 17 , or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , further comprising administering radiation.